“I think the research and development of innovative new drugs requires a long-term process. You can stand on the shoulders of giants to gain certain advantages, but it is impossible overnight. Investors choose Jiachen Xihai to value our stable construction and vision.” In early 2021, Jiachen Xihai announced the completion of a series A financing of more than 100 million yuan, led by Huachuang Capital, followed by Zheshang Venture Capital, and Fang Kaifeng Venture Capital, the lead investor of Angel Round, to continue additional investment.
